Moberg Pharma announces issue of European Patent for Kerasal Nail
May 28, 2015 02:30 ET
|
Moberg Pharma AB
STOCKHOLM, May 28, 2015. Moberg Pharma AB (OMX: MOB) today announced that the
European Patent Office has issued patent no. 2,777,689 for an improved
formulation of Moberg Pharma’s market-leading OTC...
Moberg Pharma’s partner launches Kerasal Nail in China
May 19, 2015 02:30 ET
|
Moberg Pharma AB
STOCKHOLM, May 19th, 2015. Moberg Pharma AB (OMX: MOB) today announced that its
partner, Menarini Asia-Pacific, has initiated the launch of Kerasal Nail® in
China. TV commercials and other advertising...
Moberg Pharmas partner lanserar Kerasal Nail i Kina
May 19, 2015 02:30 ET
|
Moberg Pharma AB
STOCKHOLM, 19 maj 2015. Moberg Pharma AB (OMX: MOB) meddelar idag att bolagets
partner, Menarini Asia-Pacific, har påbörjat lanseringen av Kerasal Nail® i
Kina. TV reklam och övrig marknadsföring...
BULLETIN FROM MOBERG PHARMA’S ANNUAL GENERAL MEETING 2014
May 11, 2015 13:30 ET
|
Moberg Pharma AB
STOCKHOLM, May 11, 2015. Moberg Pharma AB’s (“Company”) Annual General Meeting
took place on Monday, May 11, 2015 in the Company´s premises in Bromma.
Adoption of the income statements and the balance...
KOMMUNIKÉ FRÅN MOBERG PHARMAS ÅRSSTÄMMA 2015
May 11, 2015 13:30 ET
|
Moberg Pharma AB
STOCKHOLM, 11 april 2015. Moberg Pharma AB:s (”Bolaget”) årsstämma ägde rum
måndagen den 11 maj 2015 i Bolagets lokaler i Bromma.
Fastställande av resultat- och balansräkningarna
Årsstämman...
Moberg Pharma AB (Publ) Delårsrapport januari – mars 2015
May 11, 2015 02:00 ET
|
Moberg Pharma AB
SNABB TILLVÄXT I FÖRSÄLJNING OCH LÖNSAMHET
FÖRSTA KVARTALET
· Nettoomsättning 73,1 MSEK (47,4)
· EBITDA 17,4 MSEK (7,5)
· EBITDA för befintlig produktportfölj 25,6 MSEK (11,6)
·...
Moberg Pharma AB (Publ) Interim report January – March 2015
May 11, 2015 02:00 ET
|
Moberg Pharma AB
RAPID GROWTH IN SALES AND PROFITABILITY
FIRST QUARTER
· Revenue MSEK 73.1 (47.4)
· EBITDA MSEK 17.4 (7.5)
· EBITDA for Commercial Operations MSEK 25.6 (11.6)
· Operating profit (EBIT) MSEK...
Moberg Pharma förvärvar receptfria produkter i USA
April 27, 2015 02:00 ET
|
Moberg Pharma AB
STOCKHOLM, 27 april 2015. Moberg Pharma AB (OMX: MOB) förvärvar Balmex®, ett
väletablerat amerikanskt varumärke med flera receptfria produkter från Chattem,
Inc, Sanofis division för receptfria...
Moberg Pharma acquires U.S OTC brand Balmex®
April 27, 2015 02:00 ET
|
Moberg Pharma AB
STOCKHOLM, April 27, 2015. Moberg Pharma AB (OMX: MOB) has acquired Balmex®, a
well-established Over-The-Counter brand in the U.S. from Chattem, Inc, the U.S.
Consumer Healthcare Division of Sanofi....
Notice of Annual General Meeting in Moberg Pharma AB (publ)
April 09, 2015 11:30 ET
|
Moberg Pharma AB
Shareholders in Moberg Pharma AB (publ) (reg. no. 556697-7426) (the “Company”)
are hereby convened to the Annual General Meeting on Monday, May 11, 2015 at
5:00 p.m. in the Company´s premises in...